The goal of the present investigation is formulation and evaluation of a mucoadhesive gel for buccal delivery after solubility enhancement of very slightly water-soluble drug Miconazole Nitrate. Miconazole Nitrate is imidazole derivative useful in treatment of oropharyngeal Candidiasis, the most common infection in AIDS patients. The method namely solvent deposition with inclusion complex, solid dispersion with inclusion complex and solvent deposition with solid dispersion are used for solubility enhancement. Various polymers such as Lactose, -CD and PEG-6000 are those polymers which were used for individual methods like SolD, IC and SD respectively all the batches are evaluated for their water solubility and In-vitro release. Enhancement of dissolution rates with increasing quantity of -CD, Lactose and PEG in the complexes is observed. Water solubility of Miconazole Nitrate is enhanced up to 321.9 times by using combination of methods (solvent deposition with inclusion complex) and mucoadhesive antifungal gel of Miconazole Nitrate is prepared with improved drug release into the buccal cavity which ensures effective treatment of local fungal infection-Oropharyngeal Candidiasis.
INTRODUCTION

II of the (BCS). It is difficult to develop a new molecule
Solubilisation of poorly soluble drugs is a frequently solubility and permeability. It has been reported that encountered challenge in screening studies of new about 40% of the compounds being developed by the chemical entities as well as in formulation design and pharmaceutical industries are poorly water soluble out of development. If any drug has very less solubility, then which up to 40% of pharmacologically active new therapeutic effectiveness of that drug will be lesser molecules failed to reach the market only due to little or no because of very less systemic availability of it.
water solubility. Today pharmaceutical companies have Bioavailability is defined as the rate and extent to which been able to overcome difficulties with very slightly the active drug is absorbed from a dosage form and soluble drugs, those with aqueous solubility of less than becomes available at the site of drug action. 0.1 mg/ml present some unique challenges. These drugs Bioavailability depends on drug solubility in an aqueous are particularly good candidates for advanced environment and drug permeability through lipophilic solubilisation technologies developed by companies membranes [1] . This is a well-known fact that only specializing in drug delivery [2] . From Noyes Whitney solubilized drug molecules can be absorbed by the cellular equation, possibilities for improving drug dissolution are membranes to subsequently reach the site of drug action to increase the surface area of drug available for (Vascular system for instance). A drug can be defined dissolution by decreasing the particle size of the solid bioavailable if it belongs to the class I (High solubility and compound and/or by optimizing the wetting high permeability) of Biopharmaceutical Classification characteristics of the compound surface [3] . Therefore, System (BCS). Poorly soluble compounds belong to class various formulation strategies have been investigated to with good pharmacological activity having desired improve solubility and dissolution rate of poorly water solution or by grinding the components together or by soluble drugs such as inclusion complexation with sublimation, growth from the melt slurry preparation. It is cyclodextrins, solid dispersion, salt formation, particle size increasingly important as an alternative to salt formation, reduction, use of surfactants, co-solvency, hydrotropyetc particularly for neutral compounds. [4] . The techniques of size reduction method of increasing solubility and dissolution rates of using various milling processes are well established and acidic and basic drugs. Example of acidic or basic drug these practices are a standard part of formulation which is converted into salts has more solubility than that development. This can be done mainly by of respective drug like aspirin, theophylline, barbiturates micronisation&Nano suspension. As particle size etc.
Techniques of Solubility
decreases, surface area of particle increases resulting in Co-Crystallisation: Anew approach available for the also used for particle size reduction. enhancement of drug solubility is through the application of the co-crystals, it is also referred as molecular Modification of Crystal Habit: Polymorphism is the ability complexes. Co-crystals may be defined as crystalline of an element or compound to crystallize in more than one material that consist of two or more molecular crystalline form. Different polymorphs of drugs are (Electrical neutral) species held together by non-covalent chemically identical, but they exhibit different forces. It can be prepared by evaporation of a heteromeric physicochemical properties including solubility, melting This gives the non-polar solvent a chance to solvate the solubility of drug. Although salt formation, particle size solute molecules. reduction, etc. have commonly been used to increase dissolution rate of the drug, there are practical limitation Polymorphs: The capacity for a substance to crystallize in with these techniques the desired bioavailability more than one crystalline form is polymorphism. If the enhancement may not always be achieved. Therefore change from one polymorph to another is reversible, the formulation approaches are being explored to enhance process is called enantiotropic. If the system is bioavailability of poorly water-soluble drugs. One such monotropic, there is a transition point above the melting formulation approach that has been shown to points of both polymorphs. Polymorphs can vary in significantly enhance absorption of such drugs is to melting point. Since the melting point of the solid is formulate solid dispersion. Solid dispersion of an related to solubility, so polymorphs show different amorphous drug in a polymer matrix has been solubility. Generally the range of solubility between demonstrated to be an effective tool for solubility and different polymorphs is only 2-3 folds due to relatively subsequently, bioavailability enhancement.
small differences in free energy. It is used to enhance dissolution of hydrophobic drugs and to study its effect on crystal properties of drug. It forms drug agglomerates with number of shallow circular pits on the surface and leads to increase in solubility. The effect of application of US energy on the properties of melt sonocrystallized (MSC) valdecoxib was characterized by scanning electron microscopy (SEM), differential scanning calorimetery (DSC), X-ray powder diffraction (XRPD), infrared spectroscopy and saturated solubility studies.
Procedure:
Solid Dispersions: The term solid dispersion refers to a group of solid products consisting of at least two different components, generally a hydrophilic matrix and a hydrophobic drug; the matrix can be either crystalline or amorphous. Particle Size: Molecular dispersions, as solid dispersions, represent the last state on particle size reduction and after carrier dissolution the drug is molecularly dispersed in the dissolution medium. Solid dispersions apply this principle to drug release by creating a mixture of a poorly water soluble drug and highly soluble carriers.
Wettability:
A strong contribution to the enhancement of drug solubility is related to the drugwettability improvement verified in solid dispersions. It was observed thateven carriers without any surface activity, such as urea improved drug wettability. Carriers with surface activity such as cholic acid and bile salts when used can significantly increase the wettability property of drug. Moreover, carriers' caninfluence the drug dissolution profile by direct dissolution or co-solvent effects.
Porosity: Particles in solid dispersions have been found to have a higher degree of porosity. The increase in porosity also depends on the carrier properties; for instance, solid dispersions containing linear polymers produce larger and more porous particles than those containing reticular polymers and therefore, result in a higher dissolution rate. The increased porosity of solid dispersion particles also hastens the drug release profile.
Amorphous State: Poorly water soluble crystalline drugs, when in the amorphous state tend to have higher solubility. The enhancement of drug release can usually be achieved using the drug in its amorphous state, because no energy is required to break up the crystal lattice during the dissolution process In solid dispersions, drugs are presented as supersaturated solutions after dissolution and it is speculated that, if drugs precipitate, it is as a metastable polymorphic form with higher solubility than the most stable crystal form. For drugs with low crystal energy (Low melting temperature or heat of fusion), the amorphous composition is primarily dictated by the difference in melting temperature between drug and carrier. For drugs with high crystal energy, higher amorphous compositions can be obtained by selecting carriers, which exhibit specific interactions with them.
Disadvantages of Solid Dispersion Method [9, 10]:
The limitations solid dispersions include: 
Solvent Deposition Method:
The principle of solvent deposition technique is deposition of the drug in "minuscular form" from an organic solvent on to the surface of an inert excipient. Due to micronization the surface area of drug increases which in turn improves dissolution rate. Drug solvent deposition system (SDS) was prepared by adsorbing drug over lactose particles [14, 15] .
Procedure:
Proportions of drug: lactose. Required amount of drug powder is dissolved in organic solvent to form a clear solution.
A known amount of lactose is dispersed in the drug solution.
The solvent is evaporated at room temperature with constant stirring. Products thus obtained are kept in vacuum oven at 37°C for 24 hrs to allow complete evaporation of organic solvent. The SDS thus formed is passed through 60-mesh sieve to get dry free flowing powder. Fraction of drug powder is used for saturated solubility study [16] [17] [18] .
Current & Future Developments: Currently only 8% of new drug candidates have both high solubility and permeability. Because of solubility problems of many drugs their bioavailability gets affected and hence solubility enhancement becomes necessary. It is possible to increase the solubility of poorly water soluble drugs with the help of various techniques as mentioned above.
molecules of a specific physical and chemical nature, but to a wide range of crystalline materials, although a comprehensive knowledge of drugs at the molecular level is required to determine the appropriate approach to improve solubility and dissolution rate. A probable candidate for solubility enhancement could be Miconazole Nitrate since it belongs to BCS class II. It is a popular drug of choice for treatment of local fungal infections.
